
    
      Patients will be cohort-wise treated with clinically available kinase inhibitors for 2 weeks
      prior to standard palliative treatment. Five patients will be included in each of eight drug
      cohorts. Biopsies will be performed to determine intratumoral drug concentrations and to
      compare tissue (phospho)proteomic and kinase activity profiles before and during therapy.
    
  